Tenax Therapeutics FY Conference Summary Company Overview - **Company**: Tenax Therapeutics (NasdaqCM:TENX) - **Focus**: Development of treatments for pulmonary hypertension with heart failure preserved ejection fraction (PH-HFpEF) Clinical Trials and Development - **Current Trials**: Enrolling in a U.S. and Canadian phase 3 trial for PH-HFpEF since March 2024, targeting 230 subjects in the first half of 2026 with data expected in the second half of 2026 [2][42] - **Upcoming Trials**: Anticipation of a second phase 3 trial with a longer endpoint of 26 weeks and a global reach across approximately 15 countries [2] Market Potential - **Patient Population**: Estimated 2.2 to 3.7 million U.S. patients suffering from PH-HFpEF, characterized by significant symptoms affecting daily life [4] - **Market Size**: Addressable market estimated at $20 billion, highlighting a high unmet need with zero available drugs for this condition [40] Mechanism of Action - **Drug Mechanism**: The drug targets elevated wedge pressure rather than pulmonary artery pressure, which is a common failure point in previous trials for PH-HFpEF [8] - **Physiological Rationale**: The drug aims to reduce splenic blood volume overload, which is linked to improved hemodynamic responses and better six-minute walk test outcomes [10][11] Clinical Data Insights - **Previous Trials**: Past trials have shown that the drug can lower wedge pressure, correlating with improved six-minute walk distances, although not in a direct linear relationship [17] - **BNP Reduction**: A 23% reduction in BNP levels was observed during the transition from IV to oral levosimendan, indicating a significant effect on heart failure patients [18] Study Design and Expectations - **Control Arm Expectations**: The control group is expected to show no significant change in six-minute walk distance over time, with all benefits anticipated in the active treatment group [26] - **Sample Size Reassessment**: A blinded reassessment of sample size will occur after 150 subjects are randomized, with the potential to increase the trial size to ensure 90% power [30] Financial Position - **Funding**: The company is funded through the end of 2027, having raised $100 million over a year ago and an additional $25 million in March [42][43] - **Cash Runway**: The company expects to have more than 12 months of funding post-top line data for the LEVEL trial [42] Future Milestones - **Key Milestones**: Announcement of the last patient randomized and the start of the second trial are critical upcoming events, with significant data expected in the second half of 2026 [42]

Tenax Therapeutics Conference Call Summary Company Overview - **Company**: Tenax Therapeutics (NasdaqCM:TENX) - **Focus**: Development of TNX-103, an oral formulation of levosimendan for treating pulmonary hypertension with heart failure preserved ejection fraction (PH-HFpEF) [2][3] Key Industry Insights - **Market Need**: There is a significant unmet need for effective treatments for PH-HFpEF, as no drugs are currently approved for this condition [2] - **Research Landscape**: Tenax is not alone in this space; other investigational strategies are being evaluated for PH-HFpEF, highlighting the growing interest in this area [2] Core Development Program - **Current Studies**: - TNX-103 is in late-stage development, specifically in the phase 3 LEVEL study, with top-line data expected in the second half of 2026 [2] - LEVEL II, a global phase 3 study, is set to initiate this year [2] - **Unique Mechanism**: Tenax's approach targets a different physiological mechanism compared to other drugs in development, focusing on venous blood volume and its impact on heart function [3][5] Scientific Discussion Points - **Volume Overload**: Excessive blood volume in the heart and lungs is a critical issue in patients with PH-HFpEF, leading to symptoms and hospitalizations [5][6] - **Physiological Mechanism**: The discussion highlighted the importance of understanding the physiological changes in patients with PH-HFpEF, particularly the role of splenic blood volume and its impact on heart function [8][9] - **Proof of Concept**: Data from mechanical preload-reducing devices and nerve block studies support the hypothesis that reducing blood volume can lead to hemodynamic improvements without negatively impacting cardiac output [17][19] Clinical Trial Insights - **Phase 2 HELP Study**: Demonstrated that levosimendan significantly reduces wedge pressure during exercise, with 85% of patients responding positively [20][29] - **Transition to Oral Formulation**: Patients transitioning from IV to oral levosimendan reported improved symptoms and exercise capacity, indicating the potential for better outcomes with chronic oral administration [32][39] Comparison with Other Treatments - **Pulmonary Vasodilators**: The call discussed the limitations of existing pulmonary vasodilators in treating HFpEF, emphasizing that many trials have failed due to the complexity of the disease and the body's compensatory mechanisms [50][52] - **Relaxin Trials**: The outcomes of trials involving Relaxin analogs were discussed, highlighting the challenges faced in achieving positive results in HFpEF patients [60][61] Regulatory and Patent Considerations - **FDA Filing**: The potential for accelerated approval is contingent on the magnitude of benefit observed in the LEVEL trial, with a robust safety database being a critical requirement [67][68] - **Patent Protection**: Tenax holds multiple method of use patents for levosimendan, which are considered strong and extend to various formulations and combinations [69][70] Additional Insights - **Patient Experience**: Feedback from patients involved in the HELP and LEVEL studies indicates significant improvements in their quality of life and functional capacity [73] - **Future Directions**: The company is focused on ensuring that the transition from IV to oral formulations maintains efficacy and safety, with ongoing studies to support this [74] This summary encapsulates the key points discussed during the Tenax Therapeutics conference call, providing insights into the company's development programs, industry context, and future directions.